Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Novel PD-1 Antibody Shows Activity in Advanced Lung Cancer

By: Justine Landin, PhD
Posted: Monday, December 21, 2020

The novel PD-1 inhibitor toripalimab demonstrated antitumor activity with reportedly manageable safety profiles in patients with advanced non–small cell lung cancer (NSCLC), based on the early results of a phase I trial. In addition, Jie Wang, MD, PhD, of the Chinese Academy of Medical Sciences and Peking Union Medical College, and colleagues assessed the clinical utility of JS311, an investigational PD-L1 immunohistochemistry assay, which appeared to be consistent with three commonly used PD-L1 staining assays. Their study findings were published in JAMA Network Open.

“Promising long-term survival and a durable response were observed in patients with PD-L1 expression of at least 50%, as assessed by [the] novel PD-L1 antibody JS311. These results can contribute to the diversity of anti–PD-1/PD-L1 treatment and provide an interchangeable assay for pathological practice,” stated the study investigators.

A total of 41 patients who exhibited disease progression following at least 3 lines of chemotherapy for NSCLC were enrolled. Participants were administered a single dose of toripalimab for 28 days, followed by multidose infusions every 2 weeks. PD-L1 expression in tumor biopsies were assessed via JS311 using immunohistochemistry.

Nearly 70% of patients exhibited a median progression-free survival of 2.8 months and an overall survival of 13.8 months. When comparing PD-L1 tumor proportion scores of at least 50%, 1% to 49%, and less than 1%, median progression-free survival was 11.2 months, 2.3 months, and 2.8 months, respectively.

To verify the efficacy of JS311, three other anti–PD-L1 assays (22C3, 28-8, and SP263) were compared during staining using 280 tumor specimens. Consistency between antibodies was between 80.8% and 89.5% for tumor proportion scores of 1% and between 93.3% and 95.5% for PD-L1 tumor proportion scores of 50%.

The most common treatment-related adverse effects were rash (14.6%) and increased amylase levels (12.2%). A total of 18 patients (43.9%) experienced at least one treatment-related adverse event.

Disclosure: For full disclosures of the study authors, visit jamanetwork.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.